References
- Valeant Pharmaceuticals [Internet]. Addyi: prescribing information and medication guide. 2016 [cited 2017 Mar 30]. Available from: https://www.addyirems.com/AddyiUI/rems/pdf/prescribingInformation.pdf
- Food and Drug Administration [Internet]. Summary minutes of the advisory committee for reproductive health drugs. 2010 [cited 2017 Mar 30]. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM248751.pdf
- Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8:15–27.
- Center for Drug Evaluation and Research [Internet]. Pharmacology review of flibanserin. 2015 [cited 2017 Mar 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000PharmR.pdf
- Nair H, Woo F, Hoofnagle AN, et al. Clinical validation of a highly sensitive GC-MS platform for routine urine drug screening and real-time reporting of up to 212 drugs. J Toxicol. 2013;2013:329407.
- World Health Organization [Internet]. 1-(3-trifluoromethylphenyl)piperazine (TFMPP). WHO publication. 35th Expert committee on drug dependence. 2012 [cited 2017 Mar 30]. Available from: http://www.who.int/medicines/areas/quality_safety/5.3bExpertreviewTFMPPpre-review.pdf
- Baumann MH, Clark RD, Budzyndki AG, et al. Effects of “Legal X” piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci. 2004;1025:189–197.
- Arbo MD, Bastos ML, Carmo HF. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 2012;122:174–185.
- Elliott S. Current awareness of piperazines: pharmacology and toxicology. Drug Test Anal. 2011;3:430–438.
- Maurer HH, Kraemer T, Springer D, et al. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ectasy), piperazine, and pyrrolidinophenon types: a synopsis. Ther Drug Monit. 2004;26:127–131.
- Murphy DL, Lesch KP, Aulakh CS, et al. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev. 1991;43:527–552.